Division of Neurology News & Announcements

This week’s In The News reports on higher education vaccination policies, college athletes’ concussions, a new genetic disease, and zebrafish.

CHOP scientists share their expertise in circadian research and SMA treatments. This and more this week’s news.

The Clinical In Vivo Gene Therapy group supports CHOP’s continued leadership in the in vivo gene therapy space.

The FDA approved an oral drug, based on foundational research conducted at CHOP, to treat a rare, severe bone disease. More In The News.

When she is not hard at work in the Division of Neurology, Huijie (Jade) Feng, PhD, takes the stage as an improv actress to conquer her fears.

See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.

The FDA has granted accelerated approval of the first gene therapy for Duchenne muscular dystrophy — a major win for those affected by the debilitating disorder, CHOP experts say.

Two NIH-funded projects will track the underpinnings and natural histories of childhood epilepsies.

CHOP research paved the way for the first treatment for Friedreich’s ataxia (FA), an inherited neurodegenerative disease.

Scientists from Children’s Hospital of Philadelphia attend the American Society of Cell & Gene Therapy Annual Meeting to share their expertise through posters, panel discussions, and workshops.